Visceral leishmaniasis: Clinical sensitivity and resistance to various therapeutic agents;Leishmaniose viscérale: Efficacité clinique et résistances aux différentes molécules

Medecine Tropicale

Volumn 68, Issue 1, 2008, Pages 89-101

  Janvier, F ^a   Morillon, M ^b   Olliaro, P ^c,d  

^a SERVICE D ENDOCRINOLOGIE   (France)

^b SERVICE DE SANTÉ DES ARMÉES   (France)

^c UNICEF   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

HIV co infection; India; Resistances; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; IMIDAZOLE DERIVATIVE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

ANTIBIOTIC RESISTANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TREATMENT FAILURE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MALARIA; PATHOPHYSIOLOGY; PUBLIC HEALTH; RECOMMENDED DRUG DOSE; REVIEW; SUPERINFECTION; TREATMENT OUTCOME; TUBERCULOSIS; VISCERAL LEISHMANIASIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, VISCERAL; WORLD HEALTH;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 41649087973     PISSN: 0025682X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. MARTY P, Del GIUDICE P, DESJEUX P - Leishmanioses : aspects épidémiologique, clinique et biologique. Feuillets de Biologie 2002 ; 43 : 31-8.
2. DESJEUX P - Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004 ; 27 : 305-18.
3. KAFETZIS DA - An overview of paediatric leishmaniasis. J Postgrad Med 2003 ; 49 : 31-9.
4. ALVAR J, CANAVATE C, GUTIERREZ-SOLAR B et al. - Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin Microbiol Rev 1997 ; 10 : 298-319.
5. HARRAT Z, BERROUANE Y, BEN ABDESSLAM S et al. - Visceral leishmaniasis in Algeria. Evolution of visceral leishmaniasis in the Grande Kabylie area (1985-1990)). Arch Inst Pasteur Alger 1992 ; 58 : 255-72.
6. HARRAT Z, ADDADI K, BELKAID M, TABET-DERRAZ O - La leishmaniose viscérale en Algérie. Recensement des cas de leishmaniose viscérale (1985-1990). Bull Soc Pathol Exot 1992 ; 85 : 296-301.
7. LEGER N, DEPAQUIT J - In «Les phlébotomes». Paris, 1999.
8. ROBERTS L, HANDMAN E, FOOTE S - Leishmaniasis. BMJ 2000 ; 321 : 801-4.
9. Mc MAHON-PRATT D, ALEXANDER J - Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 2004 ; 201 : 206-24.
10. SACKS D, SHER A- Evasion of innate immunity by parasitic protozoa. Nat Immunol 2002 ; 3 : 1041-7.
11. ENGWERDA CR, ATO M, KAYE PM - Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol 2004 ; 20 : 5424-30.
12. YAMEY G, TORREELE E - The world's most neglected diseases. BMJ 2002; 325 : 176-7.
13. BUATES S, MATLASHEWSKI G - General suppression of macrophage gene expression during Leishmania donovani infection. J Immunol 2001 ; 166 : 3416-22.
14. RODRIGUEZ NE, CHANG HK, WILSON ME - Novel program of macrophage gene expression induced by phagocytosis of Leishmania chagasi. Infect Immun 2004 ; 72 : 2111-22.
15. BERTHOLET S, DICKENSHEETS HL, SHEIKH F et al. - Leishmania donovani-induced expression of suppressor of cytokine signaling 3 in human macrophages: A novel mechanism for intracellular parasite suppression of activation. Infect Immun 2003 ; 71 : 2095-101.
16. BRANDONISIO O, SPINELLI R, PEPE M - Dendritic cells in Leishmania infection. Microbes Infect 2004 ; 6 : 1402-9.
17. GUIGUEMDE RT, SAWADOGO OS, BORIES C et al. - Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg 2003; 97 : 168-9.
18. BADARO R, JONES TC, LORENCO R et al. - A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 1986 ; 154 : 639-49.
19. HO M, SIONGOK TK, LYERLY WH, SMITH DH - Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Trans R Soc Trop Med Hyg 1982 ; 76 : 741-6.
20. ROSENTHAL E, MARTY P - Les leishmanioses viscérales. La revue du praticien 2004 ; 54 : 2211-5.
21. Le FICHOUX Y, MARY C, MARTY P, KUBAR J - Diagnostic des leishmanioses. In «Dedet JP - Les leishmanioses». Ellipses ed, Paris, 1999.
22. DEDET JP - Leishmanies, leishmanioses. Biologie, clinique et thérapeutique. Encycl Med Chir, Maladies infectieuses. Editions scientifiques et médicales Elsevier SAS, Paris, 2001. 8-506-A-10.
23. de BAYSER L, ROBLOT P, RAMASSAMY A et al. - Hepatic fibrinring granulomas in giant cell arteritis. Gastroenterology 1993 ; 105 : 272-3.
24. GUERIN PJ, OLLIARO P, SUNDAR S et al. - Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002 ; 2 : 494-501.
25. SUNDAR S, SAHU M, MEHTA H et al. - Noninvasive management of Indian visceral leishmaniasis: Clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis 2002 ; 35 : 581-6.
26. DAVIDSON RN - Practical guide for the treatment of leishmaniasis. Drugs 1998; 56 : 1009-18.
27. SUNDAR S, BENJAMIN B - Diagnosis and treatment of Indian visceral leishmaniasis. J Assoc Physicians India 2003 ; 51 : 195-201.
28. ZIJLSTRA EE, EL-HASSAN AM - Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001 ; 95 Suppl 1 : 27-58.
29. PAGLlANO P, ROSSI M, RESCIGNO C et al. - Mediterranean visceral leishmaniasis in HIV-negative adults: A retrospective analysis of 64 consecutive cases (1995-2001). J Antimicrob Chemother 2003 ; 52 : 264-8.
30. LACHAUD L, DEREURE J, CHABBERT E et al. - Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J Clin Microbiol 2000 ; 38 : 236-40.
31. VEEKEN H, RITMEIJER K, SEAMAN J, DAVIDSON R - Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop Med Int Health 2003 ; 8 : 164-7.
32. BOELAERT M, RIJAL S, REGMI S et al. - A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg 2004 ; 70 : 72-7.
33. MINODIER P, NOEL G, BLANC P et al. - Management of cutaneous leishmaniasis in adults and children). Med Trop 2005 ; 65 : 487-95.
34. WEISINGER JR, PINTO A, VELAZQUEZ GA et al. - Clinical and histological kidney involvement in human kala-azar. Am J Trop Med Hyg 1978 ; 27 : 357-9.
35. BOELAERT M, LYNEN L, DESJEUX P, VAN der STUYFT P - Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis. Bull World Health Organ 1999 ; 77 : 667-74.
36. MURRAY HW - Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004 ; 71 : 787-94.
37. BERMAN JD, WADDELL D, HANSON BD - Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985 ; 27 : 916-20.
38. BERMAN JD, GALLALEE JV, BEST JM - Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987 ; 36 : 197-201.
39. SERENO D, HOLZMULLER P, MANGOT I et al. - Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob Agents Chemother 2001 ; 45 : 2064-9.
40. SUDHANDIRAN G, SHAHA C - Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J Biol Chem 2003 ; 278 : 25120-32.
41. SUNDAR S - Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001 ; 6 : 849-854.
42. SUNDAR S, MORE DK, SINGH MK et al. - Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin Infect Dis 2000 ; 31 : 1104-7.
43. OLLIARO PL, GUERIN PJ, GERSTL S et al. - Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005 ; 5 : 763-74.
44. PETERS W - The treatment of kala-azar-new approaches to an old problem. Indian J Med Res 1981 ; 73 Suppl : 1-18.
45. SUNDAR S, MEHTA H, SURESH AV et al. - Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations. Clin Infect Dis 2004 ; 38 : 377-83.
46. THAKUR CP, NARAYAN S-A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004 ; 98 : 129-38.
47. LIRA R, SUNDAR S, MAKHARIA A et al. - Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999 ; 180 : 564-7.
48. ROJAS R, VALDERRAMA L, VALDERRAMA M et al. - Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006 ; 193 : 1375-83.
49. LAURENT T, RIJAL S, YARDLEY V et al. - Epidemiological dynamics of antimonial resistance in Leishmania donovani: Genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. Infect Genet Evol 2007 ; 7 : 206-12.
50. CROFT SL, SUNDAR S, FAIRLAMB AH - Drug resistance in leishmaniasis. Clin Microbiol Rev 2006 ; 19 : 111-26.
51. ASHUTOSH, SUNDAR S, GOYAL N - Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007 ; 56 : 143-53.
52. DECUYPERE S, RIJAL S, YARDLEY V et al. - Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother 2005 ; 49 : 4616-21.
53. MARQUIS N, GOURBAL B, ROSEN BP et al. - Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol 2005 ; 57 : 1690-9.
54. SINGH N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J Med Res 2006 ; 123 : 411-22.
55. KOTHARI H, KUMAR P, SUNDAR S, SINGH N - Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani. Parasitol Int 2006 Dec 11.
56. SINGH N, SINGH RT, SUNDAR S - Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis 2003 ; 188 : 600-7.
57. SUNDAR S, PAI K, KUMAR R et al. - Resistance to treatment in Kalaazar: Speciation of isolates from northeast India. Am J Trop Med Hyg 2001 ; 65 : 193-6.
58. SUNDAR S, THAKUR BB, TANDON AK et al. - Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ 1994 ; 308: 307.
59. ALVAR J, CROFT S, OLLIARO P - Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006 ; 61 : 223-74.
60. SINGH RK, PANDEY HP, SUNDAR S - Visceral leishmaniasis (kalaazar): Challenges ahead. Indian J Med Res 2006 ; 123 : 331-44.
61. BERMAN JD, GOAD LJ, BEACH DH, HOLZ GG, Jr - Effects of ketoconazole on sterol biosynthesis by mexicana Leishmania mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol 1986 ; 20 : 85-92.
62. CROFT SL, YARDLEY V - Chemotherapy of leishmaniasis. Curr Pharm Des 2002 ; 8 : 319-42.
63. BERMAN JD, BADARO R, THAKUR CP et al. - Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998 ; 76 : 25-32.
64. BODHE PV, KOTWANI RN, KIRODIAN BG et al. - Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1999 ; 93 : 314-8.
65. MEYERHOFF A - U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999 ; 28 : 42-8 ; discussion 9-51.
66. SUNDAR S, AGRAWAL G, RAI M et al. - Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial. BMJ 2001 ; 323 : 419-22.
67. SUNDAR S, JHA TK, THAKUR CP et al. - Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: A multicenter study. Am J Trop Med Hyg 2002 ; 66 : 143-6.
68. SUNDAR S, JHA TK, THAKUR CP et al. - Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study. Clin Infect Dis 2003 ; 37 : 800-4.
69. MUELLER M, RITMEIJER K, BALASEGARAM M et al. - Unresponsiveness to AmBisome in some Sudanese patients with kalaazar. Trans R Soc Trop Med Hyg 2007 ; 101 : 19-24.
70. SUNDAR S, MEHTA H, CHHABRA A et al. - Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 2006 ; 42 : 608-613.
71. SUNDAR S, CHATTERJEE M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 2006 ; 123 : 345-52.
72. MBONGO N, LOISEAU PM, BILLION MA, ROBERT-GERO M - Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 1998 ; 42 : 352-357.
73. POURSHAFIE M, MORAND S, VIRION A et al. - Cloning of S-adenosyl-L-methionine: C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes. Antimicrob Agents Chemother 2004 ; 48 : 2409-14.
74. BRAY PG, BARRETT MP, WARD SA, DE KONING HP - Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends Parasitol 2003 ; 19 : 232-9.
75. BASSELIN M, DENISE H, COOMBS GH, BARRETT MP - Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother 2002 ; 46 : 3731-8.
76. COELHO AC, BEVERLEY SM, COTRIM PC - Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol 2003 ; 130 : 83-90.
77. MAAROUF M, LAWRENCE F, CROFT SL, ROBERT-GERO M - Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 1995 ; 81 : 421-5.
78. CHUNGE CN, OWATE J, PAMBA HO, DONNO L - Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84 : 221-5.
79. SUNDAR S, JHA TK, THAKUR CP et al. - Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007 ; 356 : 2571-81.
80. THAKUR CP, OLLIARO P, GOTHOSKAR S et al. -Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992 ; 86 : 615-6.
81. JHA TK, OLLIARO P, THAKUR CP et al. - Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998 ; 316 : 1200-5.
82. THAKUR CP, KANYOK TP, PANDEY AK et al. - Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000 ; 94 : 432-3.
83. SEAMAN J, PRYCE D, SONDORP HE et al. - Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993 ; 168 : 715-20.
84. THAKUR CP, KANYOK TP, PANDEY AK et al. - A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000 ; 94 : 429-31.
85. TEKLEMARIAM S, HIWOT AG, FROMMEL D et al. - Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 1994 ; 88 : 334-9.
86. NEAL RA, ALLEN S, Mc COY N et al. - The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 1995 ; 35 : 577-84.
87. MAAROUF M, de KOUCHKOVSKY Y, BROWN S et al. - In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp Cell Res 1997 ; 232 : 339-48.
88. MAAROUF M, ADELINE MT, SOLIGNAC M et al. - Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 1998 ; 5 : 167-73.
89. SEIFERT K, MATU S, JAVIER PEREZ-VICTORIA F et al. - Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003 ; 22 : 380-7.
90. CROFT SL, ENGEL J - Miltefosine - Discovery of the anti leishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1 : S4-8.
91. SUNDAR S, JHA TK, THAKUR CP et al. - Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 2006 ; 100 Suppl 1 : S26-33.
92. SUNDAR S, JHA TK, THAKUR CP et al. - Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002 ; 347 : 1739-46.
93. SUNDAR S, JHA TK, SINDERMANN H et al. - Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003 ; 22 : 434-8.
94. BHATTACHARYA SK, JHA TK, SUNDAR S et al. - Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004 ; 38 : 217-21.
95. SINDERMANN H, ENGEL KR, FISCHER C, BOMMER W - Oral miltefosine for leishmaniasis in immunocompromised patients: Compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004 ; 39 : 1520-3.
96. SUNDAR S, ROSENKAIMER F, MAKHARIA MK et al. - Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998 ; 352 : 1821-3.
97. De VRIES PJ, VAN der MEIDE WF, GODFRIED MH et al. - Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA. Trans R Soc Trop Med Hyg 2006 ; 100 : 1183-6.
98. SUNDAR S, MAKHARIA A, MORE DK et al. - Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31 :1110-3.
99. SINGH UK, PRASAD R, KUMAR R, JAISWAL BP - Miltefosine in children with visceral leishmaniasis. Indian Pediatr 2006 ; 43 : 1076-80.
100. SINDERMANN H, ENGEL J - Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1 : S17-20.
101. BRYCESON A - A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001 ; 6 : 928-34.
102. SUNDAR S, MURRAY HW - Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005 ; 83 : 394-5.
103. PEREZ-VICTORIA FJ, SANCHEZ-CANETE MP, SEIFERT K et al. - Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat 2006 ; 9 : 26-39.
104. PEREZ-VICTORIA FJ, CASTANYS S, GAMARRO F - Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003 ; 47 : 2397-403.
105. PEREZ-VICTORIA FJ, GAMARRO F, OUELLETTE M, CASTANYS S - Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003 ; 278 : 49965-71.
106. BJORKMAN J, NAGAEV I, BERG OG et al. - Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000; 287 : 1479-82.
107. BERMAN JD - Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am J Trop Med Hyg 1981 ; 30 : 566-9.
108. NAVIN TR, ARANA BA, ARANA FE et al. - Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992 ; 165 : 528-34.
109. BUCKNER FS, WILSON AJ, WHITE TC, VAN VOORHIS WC - Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother 1998 ; 42 : 3245-50.
110. NEAL RA, CROFT SL - An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother 1984 ; 14 : 463-75.
111. BERMAN JD, LEE LS - Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. Am J Trop Med Hyg 1983 ; 32 : 753-9.
112. SHERWOOD JA, GACHIHI GS, MUIGAI RK et al. - Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994 ; 19 : 1034-9.
113. DIETZE R, CARVALHO SF, VALLI LC et al. - Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001 ; 65 : 685-9.
114. WASUNNA MK, RASHID JR, MBUI J et al. - A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005 ; 73 : 871-6.
115. VANLERBERGHE V, DIAP G, GUERIN PJ et al. - Drug policy for visceral leishmaniasis: A cost-effectiveness analysis. Trop Med Int Health 2007 ; 12: 274-83.
116. CHUNGE CN, GACHIHI G, MUIGAI R et al. - Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985 ; 79 : 715-8.
117. GUTTERIDGE WE - TDR collaboration with the pharmaceutical industry. Trans R Soc Trop Med Hyg 2006 ; 100 Suppl 1 : S21-5.
118. GRIEKSPOOR A, SONDORP E, VOS T - Cost-effectiveness analysis of humanitarian relief interventions: Visceral leishmaniasis treatment in the Sudan. Health Policy Plan 1999 ; 14 : 70-6.
119. VEEKEN H, RITMEIJER K, SEAMAN J, DAVIDSON R - A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000 ; 5 : 312-7.
120. RITMEIJER K, VEEKEN H, MELAKU Y et al. - Ethiopian visceral leishmaniasis: Generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001 ; 95 : 668-72.
121. MURRAY HW - Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001 ; 45 : 2185-97.
122. MURRAY HW - Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches. Int J Infect Dis 2000 ; 4 : 1158-77.
123. SUNDAR S, RAI M - Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002 ; 15 : 593-8.
124. THAKUR CP, SINGH UK, HASSAN SM et al. - Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: A study of 938 cases. Trans R Soc Trop Med Hyg 1999 ; 93 : 319-23.
125. SUNDAR S - Treatment of visceral leishmaniasis. Med Microbiol Immunol 2001 ; 190 : 89-92.
126. SUNDAR S, AGRAWAL NK, SINHA PR et al. - Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997 ; 127: 133-7.
127. SUNDAR S, GUPTA LB, RASTOGI V et al. - Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000 ; 94 : 200-4.
128. SUNDAR S - Liposomal amphotericin B. Lancet 2001 ; 357 : 801-2.
129. SUNDAR S, GOYAL AK, MORE DK et al. - Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998 ; 92 : 755-64.
130. SINGH UK, PRASAD R, MISHRA OP, JAYSWAL BP - Miltefosine in children with visceral leishmaniasis: A prospective, multicentric, cross-sectional study. Indian J Pediatr 2006 ; 73 : 1077-80.
131. BHATTACHARYA SK, SUR D, KARBWANG J - Childhood visceral leishmaniasis. Indian J Med Res 2006 ; 123 : 353-6.